Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis Allegra New Prescriptions Up 9% Despite Availability Of OTC Claritin  

  • News

Executive Summary

Allegra new prescriptions are up 9% despite the availability of OTC Claritin, Aventis Chief Operating Officer Richard Markham told analysts on a fourth quarter conference call Feb. 5

You may also be interested in...



Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition

WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines

Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition

WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines

Aventis Allegra Inventory Stable At Two Weeks; Price Flexibility “Minimal”

Aventis' inventory levels for Allegra have stabilized following first quarter wholesaler reductions triggered by the availability of OTC Claritin, VP-Investor Relations Arvind Sood told investors June 29

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By